Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shares were down 2.8% during trading on Tuesday . The stock traded as low as $9.21 and last traded at $9.42, with a volume of 90,293 shares traded. The stock had previously closed at $9.69.

Several research analysts recently commented on AQXP shares. Needham & Company LLC started coverage on shares of Aquinox Pharmaceuticals in a report on Thursday, May 12th. They set a “buy” rating and a $25.00 target price for the company. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 21st. Jefferies Group increased their target price on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a report on Friday, August 5th. Finally, Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Aquinox Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $19.86.

The stock’s market capitalization is $160.42 million. The company’s 50 day moving average price is $7.92 and its 200 day moving average price is $8.46.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.22. On average, equities analysts expect that Aquinox Pharmaceuticals Inc. will post ($2.11) EPS for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.